Clinical course of patients with hepatocellular carcinoma who experienced radiologic complete response after radioembolization

被引:0
|
作者
Moon, Sungmo [1 ]
Kim, Gyoung Min [1 ]
Won, Jong Yun [1 ]
Kwon, Joon Ho [1 ]
Park, Juil [1 ]
Han, Kichang [1 ]
Kim, Man-Deuk [1 ]
Kim, Hyung Cheol [1 ]
Kim, Dong Kyu [1 ]
Choi, Jin Young [1 ]
机构
[1] Yonsei Univ, Severance Hosp, Res Inst Radiol Sci, Dept Radiol,Coll Med, Seoul, South Korea
来源
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
关键词
hepatocellular carcinoma; radioembolization; complete response; recurrence; predisposing factor; Y-90; RADIOEMBOLIZATION; SURVIVAL; EFFICACY; THERAPY; SAFETY;
D O I
10.3389/fonc.2024.1349632
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The purpose of this study is to elucidate the patterns of recurrence of hepatocellular carcinoma and to analyze factors that can predict recurrence after complete response to radioembolization.Materials and methods A total of 289 consecutive patients who underwent radioembolization for the treatment of hepatocellular carcinoma at a single tertiary center were retrospectively reviewed. Baseline characteristics were collected and compared between the group showing complete response and the group showing noncomplete response. Data on recurrence status, time to recurrence, and the patterns of recurrence among the patients who showed radiologic complete response were collected. The group that maintained complete response and the group that experienced recurrence were compared, and the risk factors affecting recurrence were evaluated by logistic regression analysis.Results The complete response rate was 24.9% (73/289). Age, sex, tumor markers, maximum tumor diameter, multiplicity, presence of vascular invasion, and target radiation dose were significantly different between the complete response and noncomplete response groups. The recurrence rate after complete response was 38.4% (28/73), and 67.9% (19/28) of recurrences occurred by 8 months after complete response. Eight patients who underwent resection/transplantation after complete response experienced no recurrence. Multiple tumors and a lower target radiation dose were independent risk factors of recurrence after complete response in the multivariate logistic regression.Conclusion Hepatocellular carcinoma recurrence following complete response after radioembolization is not uncommon and frequently occurs within 1 year after complete response. Multiple tumors and a lower target radiation dose may be risk factors for recurrence.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] CLINICAL COURSE OF SORAFENIB RESISTANT HEPATOCELLULAR CARCINOMA PATIENTS
    Woo, H. Y.
    Heo, J.
    Yoon, K. T.
    Cho, M.
    Park, S. Y.
    Tak, W. Y.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S268 - S268
  • [22] CLINICAL COURSE AND PROGNOSIS OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH HEMOPHILIA
    Imai, Norihiro
    Ishigami, Masatoshi
    Matsuda, Noritaka
    Yokoyama, Shinya
    Yamamoto, Kenta
    Ito, Takanori
    Ishizu, Yoji
    Honda, Takashi Honda
    Kawashima, Hiroki
    HEPATOLOGY, 2022, 76 : S1330 - S1330
  • [23] Clinical course of sorafenib treatment in patients with hepatocellular carcinoma
    Woo, Hyun Young
    Heo, Jeong
    Yoon, Ki Tae
    Kim, Gwang Ha
    Kang, Dae Hwan
    Song, Geun Am
    Cho, Mong
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2012, 47 (07) : 809 - 819
  • [24] Clinical course and prognosis of patients with hepatocellular carcinoma and haemophilia
    Matsuda, Noritaka
    Imai, Norihiro
    Yokoyama, Shinya
    Yamamoto, Kenta
    Ito, Takanori
    Ishizu, Yoji
    Honda, Takashi
    Okamoto, Shuichi
    Kanematsu, Takeshi
    Suzuki, Nobuaki
    Matsushita, Tadashi
    Ishigami, Masatoshi
    Kawashima, Hiroki
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2023, 35 (10) : 1211 - 1215
  • [25] Radioembolization for the treatment of unresectable hepatocellular carcinoma:A clinical review
    Saad M Ibrahim
    Robert J Lewandowski
    Kent T Sato
    Vanessa L Gates
    Laura Kulik
    Mary F Mulcahy
    Robert K Ryu
    Reed A Omary
    Riad Salem
    World Journal of Gastroenterology, 2008, (11) : 1664 - 1669
  • [26] Radioembolization for the treatment of unresectable hepatocellular carcinoma: A clinical review
    Ibrahim, Saad M.
    Lewandowski, Robert J.
    Sato, Kent T.
    Gates, Vanessa L.
    Kulik, Laura
    Mulcahy, Mary F.
    Ryu, Robert K.
    Omary, Reed A.
    Salem, Riad
    WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (11) : 1664 - 1669
  • [27] Nomogram for predicting pathologic complete response after transarterial chemoembolization in patients with hepatocellular carcinoma
    Lin, Jian
    Li, Xiaowei
    Shi, Xiaodong
    Zhang, Lei
    Liu, Hongzhi
    Liu, Jingfeng
    Wang, Kui
    Shen, Feng
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (14)
  • [28] Hepatocellular Carcinoma Pathological Response after Transarterial Radioembolization as Bridge for Liver Transplantation.
    Sanchez-Garcia, Jorge
    Riegler, Randie
    Jepperson, Maria
    Gagnon, Andrew
    Alonso, Diane
    Fujita, Shiro
    Rodriguez-Davalos, Manuel
    Thota, Ramya
    Cannon, George
    Orrock, Jared
    Krong, Jake
    Dow, Sean
    Gilroy, Richard
    Kringlen, Mark
    Zendejas-Ruiz, Ivan
    AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 : 59 - 60
  • [29] Outcomes of Surgical Resection after Radioembolization for Hepatocellular Carcinoma
    Gabr, Ahmed
    Abouchaleh, Nadine
    Ali, Rehan
    Baker, Talia
    Caicedo, Juan
    Katariya, Nitin
    Abecassis, Michael
    Riaz, Ahsun
    Lewandowski, Robert J.
    Salem, Riad
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2018, 29 (11) : 1502 - 1510
  • [30] Clinical and Radiologic Predictors of Response to Atezolizumab-Bevacizumab in Advanced Hepatocellular Carcinoma
    Choi, Se Jin
    Chung, Sung Won
    Choi, Jonggi
    Kim, Kang Mo
    Kim, Hyung-Don
    Yoo, Changhoon
    Ryoo, Baek-Yeol
    Lee, Seung Soo
    Choi, Won-Mook
    Choi, Sang Hyun
    CANCER RESEARCH AND TREATMENT, 2024, 56 (04): : 1219 - 1230